Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model

被引:2
|
作者
Folkeringa, R. J. [1 ]
Geven, L. M. [2 ]
Veldhuis, T. [2 ]
Hoogendoorn, M. [3 ]
Hofma, S. H. [1 ]
Van Roon, E. [4 ]
机构
[1] Med Ctr Leeuwarden, Dept Cardiol, NL-8934 AD Leeuwarden, Netherlands
[2] Thrombosis Serv Friesland Noord, NL-8934 AD Leeuwarden, Netherlands
[3] Med Ctr Leeuwarden, Dept Internal Med, NL-8934 AD Leeuwarden, Netherlands
[4] Med Ctr Leeuwarden, Dept Pharm, NL-8934 AD Leeuwarden, Netherlands
关键词
Atrial fibrillation; Novel oral anticoagulants; Anticoagulation; ATRIAL-FIBRILLATION; GUIDELINES; MANAGEMENT;
D O I
10.1007/s12471-014-0529-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This paper describes the implementation of novel oral anticoagulants (NOACs) through an anticoagulation nurse. Logistics and tasks of this new function are described and preliminary data are presented. Methods Indications for NOACs are explained by the treating cardiologists. Thereafter, the patient is referred to the anticoagulation nurse before starting a NOAC. After providing a patient with information and checking the creatinine clearance, co-medication and medical history, a prescription for NOAC is made. Results In 3 months, 51 patients were referred for NOAC therapy. Mean age was 68 years, CHA2DS2-VASc score was 2.9. Renal function was impaired in 28 %. Only 63 % of the patients had an uneventful start-up. NOAC therapy was withheld or prematurely stopped in 22 %. 30 % of patients needed a reduced NOAC dose. In 37 %, the anticoagulation nurse had extended patient contact, mainly because of (presumed) side effects. Conclusion Given the number of interactions that were made using a separate patient contact through the anticoagulation nurse, this seems to be an important improvement in the quality of care and deserves further expansion.
引用
收藏
页码:297 / 300
页数:4
相关论文
共 50 条
  • [21] Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control
    Janzic, Andrej
    Kos, Mitja
    PHARMACOECONOMICS, 2015, 33 (04) : 395 - 408
  • [22] Uninterrupted Novel Oral Anticoagulants and Warfarin Use for Peri-procedural Anticoagulation during Atrial Fibrillation Ablation
    Kanmanthareddy, Arun K.
    Buddam, Avanija R.
    Reddy, Madhu
    Alla, Venkata M.
    Hunter, Claire
    Lakkireddy, Dhanunjaya
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B82 - B83
  • [23] Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures
    Mar, Philip L.
    Familtsev, Dmitry
    Ezekowitz, Michael D.
    Lakkireddy, Dhanunjaya
    Gopinathannair, Rakesh
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 202 : 578 - 585
  • [24] Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis
    Komen, Joris
    Forslund, Tomas
    Hjemdahl, Paul
    Andersen, Morten
    Wettermark, Bjorn
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (03) : 642 - 652
  • [25] Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants
    Barnett-Griness, Ofra
    Stein, Nili
    Kotler, Antonio
    Saliba, Walid
    Gronich, Naomi
    HEART, 2022, 108 (04) : 266 - 273
  • [26] Effects of novel oral anticoagulants on venous thrombosis model and bleeding time assay
    Fonseca, R. J. C.
    Cortez, R. F.
    Mourao, P. A. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1091 - 1091
  • [27] Anticoagulation with Warfarin versus Novel Oral Anticoagulants in Atrial Fibrillation in Amyloid Transthyretin Amyloidosis Cardiomyopathy: A Retrospective Cohort Study
    Mitrani, Lindsey R.
    De Los Santos, Jeffeny
    Helmke, Stephen
    Biviano, Angelo B.
    Maurer, Mathew S.
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S82 - S82
  • [28] The efficacy and safety of novel oral anticoagulants versus vitamin k antagonist in transcatheter aortic valve replacement patients with indications for anticoagulation
    Abella, J.
    Vestal, M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [29] Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis
    Joyce H. S. You
    Journal of General Internal Medicine, 2014, 29 : 438 - 446
  • [30] NOVEL BLEEDING PREDICTION MODEL IN ATRIAL FIBRILLATION PATIENTS ON NEW ORAL ANTICOAGULANTS.
    Gronich, N.
    Barnett-Griness, O.
    Stein, N.
    Saliba, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S22 - S23